<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689947</url>
  </required_header>
  <id_info>
    <org_study_id>Restylane Silk for Tear Trough</org_study_id>
    <nct_id>NCT02689947</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of Restylane Silk in the Correction of Tear Trough Deformity</brief_title>
  <official_title>Evaluation of the Efficacy of Restylane Silk in the Correction of Tear Trough Deformity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nashville Centre for Laser and Facial Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nashville Centre for Laser and Facial Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective single center study to evaluate the safety and effectiveness of Restylane Silk
      for treatment of tear trough correction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome effectiveness analysis will test for the mean difference and overall improvement of radial smile lines based on baseline assessment and changes to the 6 month visit</measure>
    <time_frame>baseline to month 6</time_frame>
    <description>Primary outcome effectiveness analysis will test for the mean difference in improvement in terms of baseline to Month 6</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Tear Trough Deformity</condition>
  <arm_group>
    <arm_group_label>Restylane Silk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open label no placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Silk</intervention_name>
    <arm_group_label>Restylane Silk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy male or female between 21 and 65 years old

          2. Tear trough deformity, Hirmand Type-1 and Type-2

          3. Is voluntarily willing to consent to participate in the study

          4. Is willing to comply with all requirements of the study including being photographed,
             follow post treatment care instructions, to attend all treatment, and follow up visits

          5. Willingness to waive rights to use of still photos of themselves for research,
             marketing, or promotional reasons, including on the internet and on social media
             outlets.

          6. Willingness to refrain from other surgical, laser, or injectable treatments in the
             periorbital region during the entire duration of the study.

          7. Ability to provide informed consent.

        Exclusion Criteria:

          1. Marked delineation of the inferior orbital rim in the lateral aspect of the
             eyelid/orbit

          2. Use of botulinum toxin in the periorbital region within the past 6 months.

          3. Treatment with injectable fillers in the midface or periorbital region within the past
             2 years or treatment at any time in the past with a permanent filler in the midface or
             periorbital region such as silicone, or PMMA (Artefill)

          4. Laser skin resurfacing of the periorbital region within the past one year.

          5. History of lower eyelid blepharoplasty or periorbital surgery in tear trough region.

          6. The subject has a coagulation disorder or is currently using anti-coagulation
             medication

          7. History of facial nerve palsy.

          8. Inability to discontinue the use of nonsteroidal anti-inflammatory drugs or
             anticoagulants prior to treatment.

          9. Current participation in another active clinical trial protocol

         10. Presence of malar festoons

         11. Active cutaneous infections

         12. Allergy or sensitivity to benzocaine, lidocaine, prilocaine, or tetracaine.

         13. Pregnant or nursing females

         14. Other factors as deemed by the Principal Investigator that would make a subject
             unqualified for participation.

         15. The subject has a history of keloids or compromised wound healing

         16. The subject has a known adverse reaction to previous injection with hyaluronic acid or
             other subcutaneously injected device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

